FDA approves Qfitlia to cut bleeding episodes in patients with hemophilia
The U.S. Food and Drug Administration has approved Sanofi's Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce ...
Zacks Investment Research on MSN4h
Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure
This week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of ...
BioSpace4d
Sanofi, Alnylam Win First RNAi Approval for Hemophilia A and B
Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...
Fierce Pharma6d
Sanofi's versatile Qfitlia scores FDA nod to enter crowded hemophilia market
Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...
Sanofi’s Easier to Use Hemophilia Drug Approved by US FDA
Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US ...
Medscape6d
Fitusiran Approved for Hemophilia A, B
The US Food and Drug Administration has approved fitusiran for bleeding prophylaxis in hemophilia A and B with or without ...
Explore more
MPR3d
Qfitlia, a Novel Treatment for Hemophilia A or B, Gets FDA Approval
Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.
Medical Dialogues3d
FDA Approves fitusiran for Hemophilia A and B
The FDA has approved fitusiran, now named Qfitlia, for routine prophylaxis in patients aged 12 and older with hemophilia A or ...
Medical Dialogues3d
Fitusiran Antithrombin-Based Regimen Ensures Effective Bleed Control in Hemophilia: ATLAS‑OLE Study
The findings showed that fitusiran lowers antithrombin levels to enhance thrombin generation and restore hemostasis in ...
GEN - Genetic Engineering and Biotechnology News4d
RNAi Therapeutic for Hemophilia A or B Gets FDA Approval
Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.
BioWorld6d
Sanofi adds to hemophilia arsenal with FDA nod for Qfitlia
Sanofi SA gained U.S. FDA approval for fitusiran as a first-in-class siRNA therapy for hemophilia. Branded Qfitlia, the ...
MedPage Today7d
Fitusiran Approved for Hemophilia A and B
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved fitusiran (Qfitlia) as prophylaxis to prevent or reduce bleeding episodes in adults and children ages ...